Conquering Diseases

Study Of An Investigational Drug To Improve Lung Function For People With Cystic Fibrosis

Description

Seeking men and women aged 12 and older with cystic fibrosis of specific genotypes for a study of whether adding an investigational drug to elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) treatment improves lung function.

Overview

Participants in this study will be randomly assigned to either the study drug or placebo (looks like the investigational drug but contains no medication) in combination with elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) treatment. There are up to 20 study visits over 64 weeks that range in duration from 30 minutes to 8.5 hours.

What we're hoping for

We are studying whether adding an investigational drug to elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) treatment for cystic fibrosis improves lung function over ELX/TEZ/IVA treatment alone.

Additional Information

ClinicalTrials.gov Identifier: NCT05076149

 Principal Investigator

Ted  Kremer, MD

UMass Memorial Health Care

 Study Contact

Jaclyn  Longtine

508-856-5472

Jaclyn.Longtine@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989